1.74 USD
▼-0.02-44.75%
盘后 3.33 +2.15%
2026-08-25
市值
$2.89M
市盈率
—
EPS
-22.74
股息率
—
52 周区间
2.81 – 71.50
成交量
1.03M
Beta
0.76
目标价
—
52W 低 2.8152W 高 71.50
价格走势
公司简介
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3...